ストックスクリーナーアプリを入手
903.99
0.11%
-1.04
アフターアワーズ：
902.90
-1.09
-0.12%
Lilly Eli Co (LLY) 最新ニュース
Fed. Circ. Says Judge Wrongly Axed Teva's $177M Eli Lilly Win - Law360
Lilly to work with Gov. Braun's administration to explore nuclear energy solutions - The Journal Gazette
FDA asks drug manufacturer for more safety data on Foundayo GLP-1 - USA Today
Novo Nordisk Brings in OpenAI as NVO Stock Sits Near 52-Week Lows Amid Generic Pressure, Eli Lilly Competition - foreignpolicyjournal.com
CrossBridge Bio: Up To $300 Million Acquisition By Eli Lilly To Advance Dual-Payload ADC Cancer Therapies - Pulse 2.0
Eli Lilly acquires Houston biotech startup for $300M - Houston Chronicle
Lilly Reports 57% Lower Death Risk in Foundayo Cardiovascular St - GuruFocus
Lilly’s Foundayo lowers heart attack, stroke risk in study - USA Today
Lilly Clears Cardiovascular Overhang on Foundayo - GuruFocus
Braun signs nuclear energy-related letter of intent with Eli Lilly and Company - Fox 59
ATUM Names Genentech and Eli Lilly Veteran Gavin Barnard as Chief Scientific Officer - citybiz
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
Lilly eyes diabetes expansion for Foundayo after Phase III CV outcomes trial - FirstWord Pharma
US appeals court revives Teva lawsuit against Eli Lilly over migraine drug - Reuters
Braun administration, Eli Lilly to collaborate on nuclear power development - Indianapolis Business Journal
Leerink reiterates Eli Lilly stock rating on diabetes drug results - Investing.com
Lilly’s new obesity pill passes heart safety test in diabetes - BioPharma Dive
Is This $6.3 Billion Deal a Game Changer for Eli Lilly? - AOL.com
Eli Lilly (LLY) Stock Rises as Foundayo Obesity Pill Cuts Heart Death Risk by Over Half - CoinCentral
Gov. Mike Braun Signs Nuclear Energy Letter Of Intent With Eli Lilly And Company - InkFreeNews.com
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request - Pharmaceutical Executive
Eli Lilly Expands TuneLab With Vasa AI Tie Up For Drug Discovery - simplywall.st
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson - Benzinga
Lilly confirms date and conference call for first-quarter 2026 financial results announcement - marketscreener.com
Eli Lilly schedules April 30 webcast for first-quarter 2026 results - Stock Titan
Govenor Mike Braun signs Nuclear Energy Letter of Intent with Eli Lilly and Company - WBIW
Lilly answers FDA's call for more Foundayo safety info, plotting diabetes filing in parallel - Fierce Pharma
Lilly says Foundayo pill lowers heart attack, stroke risk in study - Reuters
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Immunocore Holdings (IMCR) - The Globe and Mail
What Is Foundayo? Eli Lilly's New Diabetes Drug Is Drawing Fresh Retail Attention - Stocktwits
Governor Braun, Eli Lilly sign letter of intent to explore nuclear energy in Indiana - wevv.com
FDA asks drugmaker Eli Lilly for more safety information on its new GLP-1 weight loss pill - The Independent
Lilly obesity pill shows no added heart risk in trial - MSN
Eli Lilly's New Oral Weight Loss Drug Clears Cardiovascular Bar - Benzinga
Eli Lilly (LLY) Announces Positive Phase 3 Results for Foundayo in Type 2 Diabetes - GuruFocus
Eli Lilly Reveals Results of Late-Stage Study for Type 2 Diabetes Treatment - WSJ
Lilly to seek FDA nod for obesity pill in diabetes (LLY:NYSE) - Seeking Alpha
Eli Lilly reports Foundayo met primary objective in Phase 3 ACHIEVE-4 study - TipRanks
Lobbying Update: $120,000 of ELI LILLY AND COMPANY lobbying was just disclosed - Quiver Quantitative
Lilly’s Foundayo meets cardiovascular safety goal in diabetes trial By Investing.com - Investing.com Canada
Lilly’s Foundayo Obesity Pill Matches Insulin in Heart Study - Bloomberg.com
Daily diabetes pill beats insulin on weight, A1C and heart safety - Stock Titan
Hedeker Wealth LLC Has $9.73 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Hardman Johnston Global Advisors LLC Acquires 20,752 Shares of Eli Lilly and Company $LLY - MarketBeat
Market Street Wealth Management Advisors LLC Has $18.14 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Sumitomo Mitsui Trust Group Inc. Sells 102,900 Shares of Eli Lilly and Company $LLY - MarketBeat
Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market - The Motley Fool
Greenup Street Wealth Management LLC Takes Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Sold by Altfest L J & Co. Inc. - MarketBeat
Gov. Mike Braun signs nuclear energy letter with Eli Lilly - nwitimes.com
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust - The Motley Fool
Eli Lilly Navigates Regulatory and Pipeline Milestones Ahead of Earnings - AD HOC NEWS
Selling pressure pushes Eli Lilly stock lower in today's trading - Traders Union
Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors - MedCity News
BMO reiterates Eli Lilly stock Outperform on manageable post-marketing requirements - Investing.com Australia
Lilly to acquire CrossBridge Bio for up to $300m - Pharmaceutical Technology
AI Models Split on Eli Lilly (LLY) as Valuation and Technicals Diverge from Fundamentals - TipRanks
Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data - BioSpace
Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million - AIM Media House
Eli Lilly bets $300m on CrossBridge Bio's dual-payload ADC platform - BioXconomy
Eli Lilly Adds CrossBridge ADCs To Broaden Oncology Growth Story - simplywall.st
FDA requests additional safety data for Eli Lilly weight-loss pill - medwatch.com
Eli Lilly to acquire biotech firm for up to USD 300m - medwatch.com
AC Immune secures CHF 10 million from Lilly to advance Alzheimer’s therapy - Greater Geneva Bern area
1.73%
0.27%
大文字化:
|
ボリューム (24 時間):